Long-term chronic toxicity testing using human pluripotent stem cell-derived hepatocytes

Drug Metabolism and Disposition

Volumn 42, Issue 9, 2014, Pages 1401-1406

  Holmgren, Gustav ^a,b   Sjögren, Anna Karin ^c   Barragan, Isabel ^d   Sabirsh, Alan ^c   Sartipy, Peter ^a,f   Synnergren, Jane ^a   Björquist, Petter ^e,f   Ingelman Sundberg, Magnus ^d   Andersson, Tommy B ^c,d   Edsbagge, Josefina ^f  

^a UNIVERSITY OF SKÖVDE   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e NovaHep AB   (Sweden)

^f Arvid Wallgrens Backe 20   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

CHEMICALLY INDUCED; DRUG EFFECTS; DRUG SCREENING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FATTY LIVER; HEPG2 CELL LINE; HUMAN; LIPIDOSIS; LIVER; LIVER CELL; PLURIPOTENT STEM CELL; PROCEDURES; TUMOR CELL LINE;

CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FATTY LIVER; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIPIDOSES; LIVER; PHARMACEUTICAL PREPARATIONS; PLURIPOTENT STEM CELLS;

EID: 84906846876     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.059154     Document Type: Article

References (38)

1. Andersson TB, Kanebratt KP, and Kenna JG (2012) The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human. Expert Opin Drug Metab Toxicol 8:909-920.10.1517/17425255.2012.685159.
2. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouët S, Morel F, Guguen-Guillouzo C, and Guillouzo A (2006) Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34:75-83.10.1124/dmd.105.006759. (Pubitemid 43042648)
3. Anthérieu S, Chesné C, Li R, Camus S, Lahoz A, Picazo L, Turpeinen M, Tolonen A, Uusitalo J, and Guguen-Guillouzo C, et al. (2010) Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab Dispos 38:516-525.10.1124/dmd.109.030197.
4. Atienzar FA, Novik EI, Gerets HH, Parekh A, Delatour C, Cardenas A, MacDonald J, Yarmush ML, and Dhalluin S (2014) Predictivity of dog co-culture model, primary human hepatocytes and HepG2 cells for the detection of hepatotoxic drugs in humans. Toxicol Appl Pharmacol 275:44-61.10.1016/j.taap. 2013.11.022.
5. Ballet F (1997) Hepatotoxicity in drug development: detection, significance and solutions. J Hepatol 26 (Suppl 2):26-36.
6. Bredberg E, Andersson TB, Frison L, Thuresson A, Johansson S, Eriksson-Lepkowska M, Larsson M, and Eriksson UG (2003) Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 42:765-777.10.2165/00003088- 200342080-00005. (Pubitemid 36976123)
7. Brolén G, Sivertsson L, Björquist P, Eriksson G, Ek M, Semb H, Johansson I, Andersson TB, Ingelman-Sundberg M, and Heins N (2010) Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage. J Biotechnol 145:284-294.10.1016/j. jbiotec.2009.11.007.
8. Chatterjee S, Richert L, Augustijns P, and Annaert P (2014) Hepatocyte-based in vitro model for assessment of drug-induced cholestasis. Toxicol Appl Pharmacol 274 :124-136.10.1016/j.taap.2013.10.032.
9. Clement B and Lopian K (2003) Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Metab Dispos 31:645-651. (Pubitemid 36444174)
10. Do J and Choi D-K (2007) Aflatoxins: detection, toxicity, and biosynthesis. Biotechnol Bioprocess Eng 12:585-593.10.1007/BF02931073.
11. Elsherbiny ME, El-Kadi AO, and Brocks DR (2008) The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci 11:147-159.
12. Gerets HH, Hanon E, Cornet M, Dhalluin S, Depelchin O, Canning M, and Atienzar FA (2009) Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: a preliminary study using a multiplexing approach. Toxicol In Vitro 23:319-332. 10.1016/j.tiv.2008.11.012.
13. Gerets HH, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, and Atienzar FA (2012) Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol 28:69-87. 10.1007/s10565-011-9208-4.
14. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, and Guguen-Guillouzo C (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 99:15655-15660.10.1073/ pnas.232137699. (Pubitemid 35403987)
15. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17.10.1146/annurev.pharmtox.39.1.1.
16. Guengerich FP, Johnson WW, Ueng YF, Yamazaki H, and Shimada T (1996) Involvement of cytochrome P450, glutathione S-transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer. Environ Health Perspect 104 (Suppl 3):557-562. (Pubitemid 26196404)
17. Guguen-Guillouzo C and Guillouzo A (2010) General review on in vitro hepatocyte models and their applications. Methods Mol Biol 640:1-40.10.1007/978- 1-60761-688-7-1.
18. Guillouzo A and Guguen-Guillouzo C (2008) Evolving concepts in liver tissue modeling and implications for in vitro toxicology. Expert Opin Drug Metab Toxicol 4:1279-1294.10.1517/17425255.4.10.1279.
19. Hannan NR, Segeritz CP, Touboul T, and Vallier L (2013) Production of hepatocyte-like cells from human pluripotent stem cells. Nat Protoc 8:430-437.
20. Jaeschke H (2007) Troglitazone hepatotoxicity: are we getting closer to understanding idiosyncratic liver injury? Toxicol Sci 97:1-3.
21. Kanebratt KP and Andersson TB (2008) HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 36:137-145.10.1124/dmd.107.017418.
22. Kassahun K, Pearson PG, Tang W, McIntosh I, Leung K, Elmore C, Dean D, Wang R, Doss G, and Baillie TA (2001) Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo: evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol 14:62-70. (Pubitemid 32064376)
23. Kaufmann P, Török M, Hänni A, Roberts P, Gasser R, and Krähenbühl S (2005) Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 41:925-935.10.1002/hep.20634. (Pubitemid 40462955)
24. Kenne K, Skanberg I, Glinghammar B, Berson A, Pessayre D, Flinois JP, Beaune P, Edebert I, Pohl CD, Carlsson S, and Andersson TB (2008) Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran. Toxicol In Vitro 22:730-746. 10.1016/j.tiv.2007.11.014
25. Khetani SR, Kanchagar C, Ukairo O, Krzyzewski S, Moore A, Shi J, Aoyama S, Aleo M, and Will Y (2013) Use of micropatterned cocultures to detect compounds that cause druginduced liver injury in humans. Toxicol Sci 132:107-117. 10.1093/toxsci/kfs326
26. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, Carlsson S, Cederbrant KE, Gibson NJ, and Armstrong M, et al. (2008) Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 8:186-195.10.1038/sj.tpj.6500458. (Pubitemid 351712643)
27. Lee WM, Larrey D, Olsson R, Lewis JH, Keisu M, Auclert L, and Sheth S (2005) Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 28:351-370. (Pubitemid 40545769)
28. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, and Bracken W, et al. (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32:56-67.10.1006/rtph.2000.1399.
29. Roberts RA, Kavanagh SL, Mellor HR, Pollard CE, Robinson S, and Platz SJ (2014) Reducing attrition in drug development: smart loading preclinical safety assessment. Drug Discov Today 19:341-347.10.1016/j.drudis.2013.11.014.
30. Sassa S, Sugita O, Galbraith RA, and Kappas A (1987) Drug metabolism by the human hepatoma cell, Hep G2. Biochem Biophys Res Commun 143:52-57. (Pubitemid 17030463)
31. Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, North PE, Dalton S, and Duncan SA (2010) Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 51:297-305.10.1002/hep.23354.
32. Szkolnicka D, Farnworth SL, Lucendo-Villarin B, Storck C, Zhou W, Iredale JP, Flint O, and Hay DC (2014) Accurate prediction of drug-induced liver injury using stem cell-derived populations. Stem Cells Transl Med 3:141-148.10.5966/ sctm.2013-0146.
33. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, and Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-872.10.1016/j.cell.2007.11.019. (Pubitemid 350138099)
34. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, and Jones JM (1998) Embryonic stem cell lines derived from human blastocysts. Science 282:1145-1147. (Pubitemid 28516247)
35. Touboul T, Hannan NR, Corbineau S, Martinez A, Martinet C, Branchereau S, Mainot S, Strick-Marchand H, Pedersen R, and Di Santo J, et al. (2010) Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology 51:1754-1765.10.1002/hep.23506.
36. Ulvestad M, Nordell P, Asplund A, Rehnström M, Jacobsson S, Holmgren G, Davidson L, Brolén G, Edsbagge J, and Björquist P, et al. (2013) Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells. Biochem Pharmacol 86:691-702.10.1016/j.bcp.2013.06.029.
37. Xu JJ, Diaz D, and O'Brien PJ (2004) Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem Biol Interact 150:115-128.10.1016/j.cbi.2004.09.011. (Pubitemid 39441298)
38. Yildirimman R, Brolén G, Vilardell M, Eriksson G, Synnergren J, Gmuender H, Kamburov A, Ingelman-Sundberg M, Castell J, and Lahoz A, et al. (2011) Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci 124:278-290. 10.1093/toxsci/kfr225